SCHEMBL31745562

SCHEMBL31745562

Cc1cccc(Oc2ccc(-c3c(C#N)c4cnccn4c3N)cc2)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.37
▸ MAPT P10636 3/20 0.37
▸ RXFP1 Q9HBX9 3/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.36
▸ GLA P06280 2/20 0.36
▸ HTT P42858 3/20 0.36
▸ TNK2 Q07912 3/20 0.35
▸ PRF1 P14222 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ GRM2 Q14416 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31745510 0.89 KDM4E (0.35) KDM4EMAPTRXFP1NPSR1GLA
SCHEMBL31745483 0.88 MAPT (0.36) KDM4EMAPTRXFP1NPSR1GLA
SCHEMBL31745440 0.85 PRF1 (0.35) KDM4EMAPTRXFP1NPSR1GLA
SCHEMBL31745428 0.84 KDM4E (0.36) KDM4EMAPTRXFP1NPSR1GLA
SCHEMBL31745482 0.84 KDM4E (0.35) KDM4EMAPTRXFP1NPSR1GLA
SCHEMBL31360456 0.83 PRF1 (0.35) KDM4EMAPTRXFP1HTTPRF1
SCHEMBL31745429 0.83 KDM4E (0.36) KDM4EMAPTRXFP1NPSR1GLA
SCHEMBL31745488 0.81 TNK2 (0.39) TNK2
SCHEMBL31745553 0.75 GRM2 (0.31) KDM4EMAPTHSD17B10GRM2MAPK1
SCHEMBL31745568 0.74 KDM4E (0.34) KDM4EMAPTRXFP1NPSR1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382297-A1 INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF INSILICO MEDICINE IP LTD (HK) 2025-12-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382297-A1 INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF FGFR3, FGFR2, FGFR1 KDM4E 3025/4885MAPT 2467/4885RXFP1 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback